| scholarly article | Q13442814 |
| P50 | author | Jesus Blazquez | Q68273789 |
| P2093 | author name string | F Baquero | |
| R Canton | |||
| I Alos | |||
| M R Baquero | |||
| P2860 | cites work | Construction and characterization of new cloning vehicle. II. A multipurpose cloning system | Q28298407 |
| An efficient method for generating proteins with altered enzymatic properties: application to beta-lactamase | Q34321482 | ||
| Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens | Q34708485 | ||
| Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests | Q35563877 | ||
| Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322 | Q37592206 | ||
| Site-directed mutagenesis at the active site of Escherichia coli TEM-1 beta-lactamase. Suicide inhibitor-resistant mutants reveal the role of arginine 244 and methionine 69 in catalysis | Q38325247 | ||
| Excitement in the beta-lactamase arena | Q38765664 | ||
| Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli | Q39819091 | ||
| Acquired resistance of Nocardia brasiliensis to clavulanic acid related to a change in beta-lactamase following therapy with amoxicillin-clavulanic acid | Q40086106 | ||
| OHIO-1 β-lactamase resistant to mechanism-based inactivators | Q44170599 | ||
| Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli | Q44358172 | ||
| Clinical isolates of Escherichia coli producing TRI beta-lactamases: novel TEM-enzymes conferring resistance to beta-lactamase inhibitors | Q54260298 | ||
| Resistance to beta-lactam/clavulanate. | Q54757712 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Escherichia coli | Q25419 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 2059-2063 | |
| P577 | publication date | 1993-10-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli | |
| P478 | volume | 37 |
| Q24677460 | A functional classification scheme for beta-lactamases and its correlation with molecular structure |
| Q36560876 | A natural polymorphism in beta-lactamase is a global suppressor |
| Q34375789 | A potent new mode of beta-lactamase inhibition revealed by the 1.7 A X-ray crystallographic structure of the TEM-1-BLIP complex. |
| Q34594475 | A secondary drug resistance mutation of TEM-1 beta-lactamase that suppresses misfolding and aggregation |
| Q33594694 | ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci |
| Q71130167 | Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents |
| Q37624545 | Amoxicillin-clavulanate therapy increases childhood nasal colonization by methicillin-susceptible Staphylococcus aureus strains producing high levels of penicillinase |
| Q33548223 | Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes |
| Q34130051 | Antibiotic synergy and antagonism |
| Q33544582 | Antimicrobial resistance |
| Q92377561 | Assessing genetic diversity and similarity of 435 KPC-carrying plasmids |
| Q54204266 | Beta-lactam resistance among Escherichia coli and Klebsiella species blood culture isolates in Finnish hospitals. Finnish Study Group for Antimicrobial Resistance. |
| Q40923467 | Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications |
| Q34510623 | Beta-lactamase nomenclature |
| Q54045958 | Beta-lactamase patterns and betalactam/clavulanic acid resistance in Escherichia coli isolated from fecal samples from healthy volunteers. |
| Q40863105 | Catalytic properties of class A beta-lactamases: efficiency and diversity |
| Q33694083 | Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 beta-lactamases from St. Louis, Missouri |
| Q35138799 | Characterization of a new TEM-derived beta-lactamase produced in a Serratia marcescens strain |
| Q33746868 | Class A beta-lactamases--enzyme-inhibitor interactions and resistance |
| Q32091274 | Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling |
| Q39331661 | Commercial Essential Oils as Potential Antimicrobials to Treat Skin Diseases |
| Q91833154 | Comparison of antibiotic resistance phenotypes in laboratory strains and clinical isolates of Staphylococcus aureus, Salmonella Typhimurium, and Klebsiella pneumoniae |
| Q35138077 | Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations. |
| Q37731521 | Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition |
| Q33692735 | Discriminatory detection of inhibitor-resistant beta-lactamases in Escherichia coli by single-strand conformation polymorphism-PCR. |
| Q33750810 | Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics |
| Q39783976 | Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant. |
| Q35820623 | Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors |
| Q37632354 | Essential oils, a new horizon in combating bacterial antibiotic resistance |
| Q54056911 | Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors. |
| Q35120519 | Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure |
| Q35120452 | First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains |
| Q39792503 | Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor |
| Q73230050 | Hydrolysis of imipenem, meropenem, ceftazidime, and cefepime by multiresistant nosocomial strains of Sphingobacterium multivorum |
| Q79162727 | Hypermutation as a Factor Contributing to the Acquisition of Antimicrobial Resistance |
| Q35120245 | Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli |
| Q39652164 | Inhibition of penicillinase by epigallocatechin gallate resulting in restoration of antibacterial activity of penicillin against penicillinase-producing Staphylococcus aureus |
| Q35139062 | Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244 |
| Q33647947 | Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics |
| Q41001966 | Ins and outs of antimicrobial resistance: era of the drug pumps |
| Q35126478 | Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates. |
| Q33977130 | Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived beta-lactamase in a clinical isolate of Klebsiella oxytoca |
| Q35111680 | Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli |
| Q48056264 | Molecular diversity and evolution of blaTEM genes encoding beta-lactamases resistant to clavulanic acid in clinical E. coli |
| Q36744818 | Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals |
| Q57074357 | Multidrug-resistant from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam |
| Q39652959 | Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors |
| Q30854268 | New beta -lactamase inhibitory protein (BLIP-I) from Streptomyces exfoliatus SMF19 and its roles on the morphological differentiation |
| Q40612622 | Non-canonical mechanisms of antibiotic resistance. |
| Q77874784 | OHIO-1 beta-lactamase mutants: the Arg244Ser mutant and resistance to beta-lactams and beta-lactamase inhibitors |
| Q34107174 | Origin and evolution of the AmpC beta-lactamases of Citrobacter freundii |
| Q33693187 | Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276. |
| Q40670277 | Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial |
| Q34614621 | Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase |
| Q39671146 | Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period |
| Q43684255 | Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance |
| Q35132416 | Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type beta-lactamases |
| Q39558648 | Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69. |
| Q37032925 | Quantifying nonspecific TEM beta-lactamase (blaTEM) genes in a wastewater stream |
| Q39657859 | Resistance to beta-lactamase inhibitor protein does not parallel resistance to clavulanic acid in TEM beta-lactamase mutants. |
| Q42166514 | Restoration of antibacterial activity of beta-lactams by epigallocatechin gallate against beta-lactamase-producing species depending on location of beta-lactamase |
| Q40289276 | SHV-49, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Klebsiella pneumoniae |
| Q33693837 | Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene |
| Q39474681 | Selection of naturally occurring extended-spectrum TEM beta-lactamase variants by fluctuating beta-lactam pressure. |
| Q34338697 | Structural and kinetic characterization of a beta-lactamase-inhibitor protein |
| Q39528655 | Structural basis for the extended substrate spectrum of AmpC BER and structure-guided discovery of the inhibition activity of citrate against the class C β-lactamases AmpC BER and CMY-10. |
| Q71394486 | Structure-based design of a potent transition state analogue for TEM-1 beta-lactamase |
| Q43578684 | Study of the in vitro activity of amoxicillin/clavulanic acid and other beta-lactam antibiotics against Escherichia coli isolated from urine specimens |
| Q40493805 | The Future of Antibacterial Chemotherapy |
| Q71942117 | The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the beta-lactamase resistance to clavulanic acid |
| Q38103861 | The intrinsic resistome of bacterial pathogens |
| Q77343418 | The role of the non-conserved residue at position 104 of class A beta-lactamases in susceptibility to mechanism-based inhibitors |
| Q27639159 | The structural bases of antibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34 |
| Q24646623 | Three decades of beta-lactamase inhibitors |
| Q44159101 | Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV beta-lactamase |
| Q24669605 | beta-Lactamases in laboratory and clinical resistance |
| Q77329372 | beta-Lactamases: protein evolution in real time |
Search more.